tbuckley/cabot-search huggingface dataset:
OP0068 SjÖgren’s syndrome in an out-patient clinic: classification of patients according to the preliminary european criteria and the proposed modified european criteria
Authors: JG Brun, TM Madland, CB Gjesdal, LT Bertelsen
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Sjögren's syndrome (SS) is defined as a chronic autoimmune condition. According to the preliminary European classification criteria<sup>1</sup> currently in use, it is possible to diagnose SS without the evidence of autoantibodies (SSA/SSB) or specific salivary gland inflammation. In Norway, these criteria are often used as a guidance for the diagnosis in the clinical setting. In the recently proposed modification of the European criteria,<sup>2</sup> the presence of autoantibodies or salivary gland inflammation is obligatory. <h3>Objectives</h3> To investigate whether out-patients with a clinical diagnosis of SS satisfied formal criteria, and the proportion of patients who satisfied the proposed modified criteria and thus had indication of an autoimmune process. <h3>Methods</h3> All out-patients with visits coded M35.0 (ICD-10) at the Rheumatology clinic from January 1, 1999 to November 1, 2000, were included in the study. Patients with secondary SS, observational patients and those misclassified were excluded. <h3>Results</h3> Of 10720 consultations, 457 (4,3%) were coded M35.0. Patients typically had 1–3 consultations in the period. After exclusions, there remained 203 patients who were coded correctly according to the clinical diagnosis in the journal. Of these, 116 (57.1%) satisfied the current European criteria, and 83 (40.9%) satisfied the proposed modified criteria. Thirty-four (29.3%) of the patients satisfying current criteria lost the diagnosis of SS according to the modified criteria, while only one patient who did not previously satisfy criteria received the diagnosis. <h3>Conclusion</h3> Sicca-symptoms and signs may have a variety of causes. In our study only 40.9% of the patients with a clinical diagnosis of SS satisfied the proposed modified European criteria and had evidence of SS as an autoimmune condition. Approximately one third of the patients meeting the preliminary European criteria for SS, lost the diagnosis according to the modified criteria. <h3>References</h3> Vitali C, Bombardieri S, Moutsopoulos HM, <i>et al</i>. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36:340–7 Vitali C, Bombardieri S, Moutsopoulos HM, and the European Study Group for the Classification Criteria for Sjögren's syndrome. A proposal for modification of the European classification criteria for Sjögren's syndrome (Abstract). Clin Exp Rheum. 2000;18:118
My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype
Authors: Yadi Zhou, Junfei Zhao, Jiansong Fang, William Martin, Lang Li, Ruth Nussinov, Timothy A. Chan, Charis Eng, Feixiong Cheng
Journal: Genome biology (2021)

Massive genome sequencing data have inspired new challenges in personalized treatments and facilitated oncological drug discovery. We present a comprehensive database, My Personal Mutanome (MPM), for accelerating the development of precision cancer medicine protocols. MPM contains 490,245 mutations from over 10,800 tumor exomes across 33 cancer types in The Cancer Genome Atlas mapped to 94,563 structure-resolved/predicted protein-protein interaction interfaces ("edgetic") and 311,022 functional sites ("nodetic"), including ligand-protein binding sites and 8 types of protein posttranslational modifications. In total, 8884 survival results and 1,271,132 drug responses are obtained for these mapped interactions. MPM is available at https://mutanome.lerner.ccf.org .
Gastrocolic fistula: an unusual presentation of colon cancer
Authors: Rodrigo Dorelo, Adrián Canavesi, Joaquin Berrueta, Marcos Leites
Journal: Endoscopy (2021)

An 80-year-old man with a prior history of hypertension attended the emergency room with a history of abdominal pain, nausea, and coffee ground vomitus with a feculent odor. Prior to this admission, he had nonspecific abdominal discomfort with an objective weight loss of 44 pounds in the last year.
Percentage of Adolescents Meeting Federal Fruit and Vegetable Intake Recommendations — Youth Risk Behavior Surveillance System, United States, 2017
Authors: Samantha J. Lange, Latetia V. Moore, Diane M. Harris, Caitlin L. Merlo, Seung Hee Lee, Zewditu Demissie, Deborah A. Galuska
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

According to the 2020-2025 Dietary Guidelines for Americans, persons should consume fruits and vegetables as part of a healthy eating pattern to reduce their risk for diet-related chronic diseases, such as cardiovascular disease, type 2 diabetes, some cancers, and obesity.*A healthy diet is important for healthy growth in adolescence, especially because adolescent health behaviors might continue into adulthood (1).The U.S. Department of Agriculture (USDA) recommends minimum daily intake of 1.5 cups of fruit and 2.5 cups of vegetables for females aged 14-18 years and 2 cups of fruit and 3 cups of vegetables for males aged 14-18 years.† Despite the benefits of fruit and vegetable consumption, few adolescents consume these recommended amounts (2-4).In 2013, only 8.5% of high school students met the recommendation for fruit consumption, and only 2.1% met the recommendation for vegetable consumption (2).To update the 2013 data, CDC analyzed data from the 2017 national and state Youth Risk Behavior Surveys (YRBSs) to describe the percentage of students who met intake recommendations, overall and by sex, school grade, and race/ethnicity.The median frequencies of fruit and vegetable consumption nationally were 0.9 and 1.1 times per day, respectively.Nationally, 7.1% of students met USDA intake recommendations for fruits (95% confidence interval [CI] = 4.0-10.3)and 2.0% for vegetables (upper 95% confidence limit = 7.9) using previously established scoring algorithms.State-specific estimates of the percentage of students meeting fruit intake recommendations ranged from * https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf.† These amounts are appropriate for persons who get <30 minutes per day of moderate physical activity, beyond normal daily activities.Those who are more physically active might be able to consume more while staying within calorie needs.https://www.choosemyplate.gov/eathealthy/vegetables,https://www.choosemyplate.gov/eathealthy/fruits. 4.0% (Connecticut) to 9.3% (Louisiana), and the percentage meeting vegetable intake recommendations ranged from 0.6% (Kansas) to 3.7% (New Mexico).Additional efforts to expand the reach of existing school and community programs or to identify new effective strategies, such as social media approaches, might help address barriers and improve adolescent fruit and vegetable consumption.The Youth Risk Behavior Surveillance System monitors prevalence of youth health behaviors that contribute to the leading causes of death and disability at the national, state, territorial, tribal, and large urban school district levels.§ Students
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells
Authors: Wenting Pan, Zhouwei Zhang, Hannah Kimball, Fangfang Qu, Kyler Berlind, Konrad H. Stopsack, Gwo-Shu Mary Lee, Toni K. Choueiri, Philip W. Kantoff
Journal: Clinical Cancer Research (2021)

Abiraterone acetate (AA), an inhibitor of cytochrome P450 17alpha-hydroxylase/17, 20 lyase, is an FDA-approved drug for advanced prostate cancer. However, not all patients respond to AA, and AA resistance ultimately develops in patients who initially respond. We aimed to identify AA resistance mechanisms in prostate cancer cells.We established several AA-resistant cell lines and performed a comprehensive study on mechanisms involved in AA resistance development. RNA sequencing and phospho-kinase array screenings were performed to discover that the cAMP-response element CRE binding protein 1 (CREB1) was a critical molecule in AA resistance development.The drug-resistant cell lines are phenotypically stable without drug selection, and exhibit permanent global gene expression changes. The phosphorylated CREB1 (pCREB1) is increased in AA-resistant cell lines and is critical in controlling global gene expression. Upregulation of pCREB1 desensitized prostate cancer cells to AA, while blocking CREB1 phosphorylation resensitized AA-resistant cells to AA. AA treatment increases intracellular cyclic AMP (cAMP) levels, induces kinases activity, and leads to the phosphorylation of CREB1, which may subsequently augment the essential role of the CBP/p300 complex in AA-resistant cells because AA-resistant cells exhibit a relatively higher sensitivity to CBP/p300 inhibitors. Further pharmacokinetics studies demonstrated that AA significantly synergizes with CBP/p300 inhibitors in limiting the growth of prostate cancer cells.Our studies suggest that AA treatment upregulates pCREB1, which enhances CBP/p300 activity, leading to global gene expression alterations, subsequently resulting in drug resistance development. Combining AA with therapies targeting resistance mechanisms may provide a more effective treatment strategy.
Abstract 11803: The Estrogen-related Receptor Coordinates Transcription of Genes Involved in Mitochondrial and Contractile Maturation in Human Induced Pluripotent Stem Cell-derived Cardiac Myocytes
Authors: Tomoya Sakamoto, Shibiao Wan, Junil Kim, Kyoung Jae Won, Daniel P Kelly
Journal: Circulation (2019)

Cardiac myocyte differentiation involves robust mitochondrial biogenesis and maturation coincident with changes in contractile proteins and ion channels including canonical switches from fetal to a...
Moving Patient Care Forward in the Biden Era
Authors: Robert Steinbrook, Mitchell H. Katz, Rita F. Redberg
Journal: JAMA Internal Medicine (2021)

is inaugurated as the 46th president of the United States on January 20, 2021, the chaos of the Trump era 1 should eventually begin to fade and the formidable task of controlling and ending the coronavirus disease 2019 (COVID-19) pandemic must move forward in earnest.The speed and effectiveness of the response is likely to define the Biden era.COVID-19 has dwarfed the myriad of other health care challenges, and removing its threat, which has paralyzed the country since March 2020, will determine whether the new administration will be able to restore trust in the competence of the US government with regard to science and public health.The response to COVID-19 will also influence whether Democrats and Republicans in the 117th Congress can find sufficient common ground to work with the Biden administration to address other pressing health policy issues.The long list includes the continuing effects of systemic racism on health inequities; an underfunded public health system; the future of the Affordable Care Act, health insurance for the approximately 29 million nonelderly individuals in the US who remain uninsured 2 ; and the high costs of prescription drugs.However, there are some steps that the Biden administration can take without waiting for Congress, such as resuming a leadership role in global public health by promptly rejoining the World Health Organization and spearheading the international effort to address climate change.When Biden takes office, more than 400 000 people in the US will have died from COVID-19, 3 with no definite end in sight to the tragic number of new cases and deaths.It is a national disgrace that with only 4% of the world's population, the US accounts for nearly 20% of all COVID-19 deaths. 4There is a disturbing disconnect between the heroic efforts of physicians, nurses, and other health care professionals to save lives, 5 and the practical difficulties of mobilizing widespread political and public support for common-sense actions to prevent new cases and deaths.The pandemic has made glaringly clear the risks to the nation of an inadequate public health infrastructure that would be incapable of mounting a speedy and well-coordinated national response to the next pandemic.Making progress against the pandemic will require strong federal leadership and the empowerment of career federal scientists and public health officials at the US Food and Drug Administration, the Centers for Disease Control and Prevention, and other agencies.For the foreseeable future, organized and
Methodological issues of systematic reviews and meta-analyses in the field of sleep medicine: A meta-epidemiological study
Authors: Chang Xu, Luis Furuya-Kanamori, Joey S.W. Kwong, Sheng Li, Yu Liu, Suhail A. Doi
Journal: Sleep Medicine Reviews (2021)

An increasing number of systematic reviews and meta-analyses (SRMAs) have been published in the field of sleep medicine. We evaluated the methodological issues of these SRMAs. A protocol was developed in advance. Three databases were searched from inception to October 2019 for SRMAs published in major academic journals of sleep medicine that assessed healthcare interventions. The AMSTAR 2.0 instrument was used to evaluate the methodological issues and a multivariable regression analysis was conducted to investigate potential measures associated with methodological validity. We identified 163 SRMAs. The median number of missing safeguards of these SRMAs was 7 out of 16 (Interquartile range, IQR: 6-9), and on average, two of these missing safeguards were critical weaknesses. Our regression analysis suggested that SRMAs published in recent years (β = 0.16; 95%CI: 0.08, 0.24; p = 0.002), with the first author from Europe (β = 0.08; 95%CI: 0.02, 0.14; p = 0.013) tend to have higher relative methodological ranks. In conclusion, the methodological validity for current SRMAs in sleep medicine was poor. Further efforts to improve the methodological validity are needed.
AB0220 Ochronotic spondyloarthropathy with multisystemic involvement: a case report
Authors: K Nas, A Gür, R Çevik, AJ Saraç, S Söker (Çakmak), S Em, M Karakoç, S Kilinç
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Ochronosis is a musculoskeletal manifestation of alcaptonuria, a rare hereditery metabolic disorder characterised by the absence of the enzyme homogentisic acid oxidase and associated with various systemic abnormalites related to the deposition of homogentisic acid pigment. <h3>Objectives</h3> We aimed to review a case with ochronosis, a disorder of rare and multisystemic involvement, in the light of literature. <h3>Methods</h3> A housewife, 53 years of age, was admitted to our clinic with complaints of low back and left shoulder pains. Due to low-back pain complaints, she was operated on two times with diagnosis of lumbar discal hernia. <h3>Results</h3> The radiographic appearance in the lumbar spine of the patients was almost pathogonomic of ochronotic spondyloartropathy. Thypical water-like calcifications were seen in the intervertebral discs, with narrowing of disc spaces and osteoporotic rarefaction of the vertebral bodies. Shoulder joint, narrowing of the joint space, a marked subchondral sclerosis, and small osteophytes were observed; similarly, knee, sacroiliac joints and symphysis pubis show at narrowing of the joint spaces and subchondral bone sclerosis. In the eyes of the patient, ochronotic pigmentation was seen by light microscopy. The blue-black pigmentation was bilateral and asymmetric in the cornea, conjunctiva and sclera. In addition, black-grey pigmentation was present in the ear cartilage and hand nails. In the laboratory test, homogentisic acid was found increase (2740 mmol HjA/mmol creatinin; N: 10 mmol HjA/mmol) creatinin in urine. <h3>Conclusion</h3>
Cell-Based Biohybrid Sensor Device for Chemical Source Direction Estimation
Authors: H. Oda, K. Kihara, Y. Morimoto, S. Takeuchi
Journal: Cyborg and Bionic Systems (2021)

This paper describes a method to estimate the direction from which the signal molecule reaches the sensor by using living cells. In this context, biohybrid sensors that utilize a sophisticated sensing system of cells can potentially offer high levels of chemical-detection sensitivity and selectivity. However, biohybrid-sensor-based chemical-source-direction estimation has not received research attention because the cellular response to chemicals has not been examined in the context of directional information. In our approach, we fabricated a device that can limit the interface between the cell-laden hydrogel and the chemical solution of interest to enhance the time difference over which the chemical solution reaches the cells. Chemical detection by cells that express specific receptors is reflected as the fluorescence of the calcium indicator within the cells. Our device has eight chambers that each house 3D cell-laden collagen hydrogels facing circularly outward. The device also works as a cover to prevent chemicals from permeating the hydrogel from above. In our study, by observing the time course of the fluorescence emission of each chamber, we were able to successfully estimate the chemical-source direction within an error range of 7–13°. Our results suggest that a combination of microstructure devices embedded with living cells can be used to exploit cell functionalities to yield chemical-source directional information.
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Authors: Anja Strangfeld, Martin Schäfer, Milena A Gianfrancesco, Saskia Lawson-Tovey, Jean W Liew, Lotta Ljung, Elsa F Mateus, Christophe Richez, Maria J Santos, Gabriela Schmajuk, Carlo A Scirè, Emily Sirotich, Jeffrey A Sparks, Paul Sufka, Thierry Thomas, Laura Trupin, Zachary S Wallace, Sarah Al-Adely, Javier Bachiller-Corral, Suleman Bhana, Patrice Cacoub, Loreto Carmona, Ruth Costello, Wendy Costello, Laure Gossec, Rebecca Grainger, Eric Hachulla, Rebecca Hasseli, Jonathan S Hausmann, Kimme L Hyrich, Zara Izadi, Lindsay Jacobsohn, Patricia Katz, Lianne Kearsley-Fleet, Philip C Robinson, Jinoos Yazdany, Pedro M Machado
Journal: Annals of the Rheumatic Diseases (2021)

To determine factors associated with COVID-19-related death in people with rheumatic diseases.
Impact of Anti-Hepatitis B Core Following Allogeneic Bone Marrow Transplantation; Single Center Study of 489 Patients
Authors: Muhned Alhumaid, Syed Osman Ali Ahmed, Fahad Al Mohareb, Fahad Z. Alsharif, Hazzaa Alzahrani, Naeem A. Chaudhri, Raid El Fakih, Amr Hanbali, Shahrukh K. Hashmi, Said Yousuf Ahmed, Walid Rasheed, Marwan Shaheen, Tusneem Elhassan, Feras Abdulaziz Alfraih
Journal: Blood (2017)
New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK
Authors: Roger Williams, Charles Alessi, Graeme Alexander, Michael Allison, Richard Aspinall, Rachel L Batterham, Neeraj Bhala, Natalie Day, Anil Dhawan, Colin Drummond, James Ferguson, Graham Foster, Ian Gilmore, Raphael Goldacre, Harriet Gordon, Clive Henn, Deirdre Kelly, Alastair MacGilchrist, Roger McCorry, Neil McDougall, Zulfiquar Mirza, Kieran Moriarty, Philip Newsome, Richard Pinder, Stephen Roberts, Harry Rutter, Stephen Ryder, Marianne Samyn, Katherine Severi, Nick Sheron, Douglas Thorburn, Julia Verne, John Williams, Andrew Yeoman
Journal: The Lancet (2021)
Effect of Tidal Volume on Pulmonary Outcomes After Surgery
Authors: Varun Suresh
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0036 CHILDREN WITH EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS HAVE A CYTOKINE PATTERN FAVOURING B CELL ACTIVATION IN CIRCULATION
Authors: R. A. Moura, F. Oliveira-Ramos, C. Marques, A. Brito, R. L. Teixeira, V. C. Romão, R. Campanilho-Marques, V. Teixeira, M. J. Saavedra, C. Ponte, N. Khmelinskii, J. E. Fonseca
Journal: Annals of the Rheumatic Diseases (2020)

Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The majority of polyarticular JIA (pJIA) and a large fraction of extended oligoarticular JIA (oJIA) patients fulfil classification criteria for rheumatoid arthritis (RA) in adulthood. B-cells play several important roles in RA pathogenesis, but it is still unclear if the pattern of B-cell involvement in pJIA and extended oJIA follows what has been described for adults with RA. Objectives: The main goal of this study was to determine the concentration of cytokines potentially relevant for B-cell activation in serum from children with pJIA and extended oJIA when compared to children with persistent oJIA, adult JIA, early and established RA. Methods: Serum samples were collected from children with extended oJIA (n=8), persistent oJIA (n=6), pJIA (n=6), adult JIA (n=8), untreated early RA (&lt;1 year of disease duration, n=12), established RA patients treated with synthetic disease-modifying anti-rheumatic drugs (DMARDs) (n=10) and two groups of age- and sex-matched healthy donors (children, n=6 and adults, n=10). A proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), interleukin (IL)-6 and IL-21 serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: Children with extended oJIA, early and established RA patients had significantly higher BAFF serum levels when compared to controls, but no significant differences were observed in children with persistent oJIA, pJIA and adult JIA when compared to all groups included. APRIL serum levels were significantly increased in early and established RA patients when compared to both controls and children with persistent oJIA. No significant differences were found in APRIL concentrations between children with JIA, adult JIA and controls. IL-6 serum levels were significantly increased in children with extended oJIA, pJIA, early and established RA when compared to controls, but no significant differences were found in children with persistent oJIA and adult JIA patients. IL-21 serum levels were significantly increased in early RA when compared to controls, but no significant differences were observed between any of the other groups included. Conclusion: The similarity in B-cell cytokine pattern found between extended oJIA, pJIA, early and established RA patients, contrarily to what was observed in persistent oJIA, suggests an early B-cell involvement in the pathogenesis of extended oJIA and pJIA as described for RA. Disclosure of Interests: None declared
Dietary table grape protects against ultraviolet photodamage in humans: 2. molecular biomarker studies
Authors: Allen S.W. Oak, Rubina Shafi, Mahmoud Elsayed, Bharat Mishra, Sejong Bae, Stephen Barnes, Mahendra P. Kashyap, Andrzej T. Slominski, Landon S. Wilson, Mohammad Athar, Craig A. Elmets
Journal: Journal of the American Academy of Dermatology (2021)